Picture of MedCap AB (publ) logo

MCAP — MedCap AB (publ) News Story

0.000.00%
se flag iconLast trade - 00:00
FinancialsSpeculativeMid CapHigh Flyer

Sweden's MedCap Q1 net sales rise 13% on organic growth and acquisitions

Overview

Sweden life sciences investor's Q1 net sales rose 13% yr/yr, driven by organic growth and acquisitions

Adjusted EBITA for Q1 grew 30%, with margin rising to 19.7%

Company says all business areas contributed to growth, with MedTech showing strong organic gains

Outlook

Company expects gradual margin improvement in Specialty Pharma in H2 and coming years

MedCap says conditions for acquisitions remain favourable and plans to continue completing deals

Company says external uncertainty has not materially impacted sales but remains cautious about indirect effects

Result Drivers

MEDTECH ORGANIC GROWTH - Co said MedTech segment delivered solid organic net sales growth, with nutrition and ECG vacuum systems standing out

ACQUISITIONS - Acquisitions contributed to growth in Assistive Tech and Specialty Pharma, with XGX Pharma acquisition driving Specialty Pharma net sales

FAVOURABLE PRODUCT MIX - Favourable product mix in Abilia and the acquisition of LivAssured contributed positively to Assistive Tech performance

Company press release: ID:nMFN91bLf4

Key Details

MetricBeat/MissActualConsensus Estimate
Q1 RevenueSEK 556.60 mln
Q1 EPSSEK 3.70
Q1 Net IncomeSEK 55.70 mln
Analyst Coverage The one available analyst rating on the shares is "buy" The average consensus recommendation for the investment management & fund operators peer group is "buy" Wall Street's median 12-month price target for MedCap AB (publ) is SEK621.50, about 33% above its April 28 closing price of SEK467.40 The stock recently traded at 23 times the next 12-month earnings vs. a P/E of 28 three months ago For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com. (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on MedCap AB (publ)

See all news